VEXT Stock Overview
Through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vext Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.17 |
| 52 Week High | CA$0.42 |
| 52 Week Low | CA$0.14 |
| Beta | 1.69 |
| 1 Month Change | -5.41% |
| 3 Month Change | -10.26% |
| 1 Year Change | -46.15% |
| 3 Year Change | -68.18% |
| 5 Year Change | -76.67% |
| Change since IPO | -87.50% |
Recent News & Updates
Recent updates
It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks
Oct 24
Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper
Jun 18There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding
Jan 16Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?
Sep 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Aug 16Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Jan 17Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now
Dec 09We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt
Sep 29Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly
Apr 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Nov 15Is Vext Science (CSE:VEXT) A Risky Investment?
Jul 15Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)
Apr 25Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?
Jan 15Shareholder Returns
| VEXT | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 2.9% | 0.9% | 2.6% |
| 1Y | -46.2% | -42.8% | 17.7% |
Return vs Industry: VEXT underperformed the Canadian Pharmaceuticals industry which returned -41% over the past year.
Return vs Market: VEXT underperformed the Canadian Market which returned 17.2% over the past year.
Price Volatility
| VEXT volatility | |
|---|---|
| VEXT Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 12.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 18.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: VEXT's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: VEXT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Eric Offenberger | www.vextscience.com |
Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch, Appalachian Pharm, Herbal Wellness, and Revibe brands.
Vext Science, Inc. Fundamentals Summary
| VEXT fundamental statistics | |
|---|---|
| Market cap | CA$42.07m |
| Earnings (TTM) | -CA$10.86m |
| Revenue (TTM) | CA$48.97m |
0.9x
P/S Ratio-4.0x
P/E RatioIs VEXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VEXT income statement (TTM) | |
|---|---|
| Revenue | US$34.22m |
| Cost of Revenue | US$25.51m |
| Gross Profit | US$8.71m |
| Other Expenses | US$16.30m |
| Earnings | -US$7.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 25.45% |
| Net Profit Margin | -22.19% |
| Debt/Equity Ratio | 42.7% |
How did VEXT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 04:02 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vext Science, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matt Bottomley | Canaccord Genuity |
| Shaan Mir | Canaccord Genuity |
| Neal Gilmer | Haywood Securities Inc. |